At a glance
ClinicalIndex Comparison RecordN/ATerminated· 9 enrolled
Drug / intervention
Cardio formulation +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomized, Placebo-controlled, Parallel Design Study to Evaluate the Effects of the Cardio Formulation on Oxidized LDL in Individuals Who Are Overweight to Mildly Obese and Otherwise Healthy
In Brief
A clinical study evaluating Cardio formulation and Placebo for Oxidized Low Density Lipoprotein. Terminated early, enrolled 9 participants across 1 site.
Signals
Trial was terminated early
Detailed Summary
The purpose of this study is to assess the efficacy and safety of the Cardio formulation in reducing oxidized LDL \[(Ox LDL (low density lipoprotein)\] in overweight to mildly obese generally healthy adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOxidized Low Density Lipoprotein
CountriesUnited States
Collaborators--
Timeline
N/ATerminatedFinished
2020202120222023202420252026
Enrollment StartDec 2019
First PostedMar 2020
Primary CompletionNov 2021
TodayJul 2026
First PostedMar 23, 2020
Enrollment StartDec 10, 2019
Primary CompletionNov 19, 2021
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 6.3 years ago
Interventions
Cardio formulationdietary
Tomato-based formulation with dietary supplement softgels
Placebodietary
Placebo softgels